Neuro Event Labs

Neuro Event Labs operates at the intersection of digital health, neurological diagnostics, clinical monitoring, and healthcare software. Its differentiation is the combination of non-contact video and audio capture, machine-learning event detection, interactive physician reporting, and optional expert review. That workflow targets a specific clinical problem: generating more objective and usable information about epileptic seizures in hospitals and at home, rather than relying only on episodic observation or patient recollection. The company has a narrower specialization than general remote-patient-monitoring vendors and a more clinically focused proposition than broad computer-vision platforms. The Nelli Seizure Monitoring System also gives the business a regulated medical-device pathway, reinforced by the reported FDA 510(k) clearance announced on Dec 3, 2025. Its disclosed categories and €6.78 million in cumulative financing indicate a focused growth-stage company rather than a scaled diagnostics incumbent. The main strategic question is whether regulatory clearance and clinical workflow integration can support adoption beyond its Finnish hospital-development base.

Neuro Event Labs’ trajectory shows a progression from early-stage clinical software development to regulated medical-device commercialization. The company was founded on Sep 5, 2015, raised an undisclosed seed round with Maki.vc on Mar 14, 2018, and secured a €1,881,250 grant in 2020. On Apr 9, 2020, it announced a €3.9 million Series A involving the European Innovation Council, Hadean Ventures, Maki.vc, and SHS Capital. A further €1 million convertible note was announced on Jul 10, 2023, bringing disclosed cumulative funding to $7,385,416 on a normalized basis. The clearest recent inflection point is regulatory: Nelli received FDA 510(k) clearance for hospital use in the United States, with the related announcement dated Dec 3, 2025 and product-launch timing recorded as Jan 1, 2026. This expands the addressable market beyond the company’s Finnish clinical-development roots. However, the available profile does not document employee growth, revenue, additional financing after 2023, or a broad commercial rollout. Growth should therefore be interpreted as regulatory and product maturation, with scale-up still requiring further evidence.